Every material Form 8-K LB PHARMACEUTICALS INC has filed with the SEC since September 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LB Pharmaceuticals reported a third-quarter 2026 net loss of $59.1 million, or $1.79 per share, compared with $3.6 million a year earlier, as research and development spending rose to $51.5 million from $2.4 million. The company reported cash, cash equivalents and short-term investments of $403.8 million and said this should fund operations beyond the second quarter of 2029, while it remains on track for topline data from the Phase 3 NOVA-2 trial in the first half of 2027.
Net loss was $59.1 million for the quarter ended September 30, 2026, versus $3.6 million a year earlier; net loss per share was $1.79 versus $0.61.
Research and development expenses were $51.5 million, versus $2.4 million, mainly for the Phase 3 trial of LB-102 in acute schizophrenia and the Phase 2 bipolar depression trial.
Cash, cash equivalents and short-term investments were $403.8 million as of September 30, 2026, up from $295.2 million at December 31, 2025.
Topline data from the Phase 3 NOVA-2 trial are expected in the first half of 2027.
LB Pharmaceuticals named Susan G. Kozauer, M.D. as its Chief Medical Officer, effective September 14, 2026, with a $515,000 base salary and an option to buy 200,000 shares. The company says she will lead clinical development of LB-102 ahead of Phase 3 NOVA-2 topline results expected in the first half of 2027.
Effective start date: September 14, 2026; base salary $515,000 with a 40% target bonus
One-time sign-on bonus of $150,000, with a 200,000-share option subject to four-year vesting
Severance: nine months of base salary and COBRA for up to nine months; enhanced terms apply within the change-of-control window
CEO Heather Turner said Phase 3 NOVA-2 topline results are expected in the first half of 2027
LB Pharmaceuticals appointed Joseph Miller as chief financial officer, effective September 2, 2026, replacing no named predecessor in the filing. Miller previously served as CFO of Aurinia Pharmaceuticals from April 2020 to March 2026, and the filing states his employment agreement sets a $530,000 base salary and a 40% target bonus, along with a 200,000-share stock option.
Start date: September 2, 2026; announced September 3, 2026
Base salary $530,000; target bonus 40% of base salary; employment is at will
Inducement option for 200,000 shares of common stock, vesting over four years with 25% after the first anniversary of the start date
Severance: nine months of base salary if terminated without cause outside a change of control; larger package of one year base salary plus 150% of target bonus within 3 months before or 12 months after a change of control
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LB PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →